Stock Movers: Snowflake, Veeva, Williams Sonoma

Scott Peters
27 Aug, 2025
New York City

Snowflake Inc. increased 13.2% to $226.83 after the cloud-based data storage company reported a 32% increase in revenue and the net loss shrank in the latest quarter ending on July 31.

Consolidated revenue increased to $1.14 billion from $868 million, net loss declined to $298 million from $316.9 billion, and diluted losses per share decreased to 89 cents from 95 cents a year ago.

The company guided product revenue for the next quarter to range between $1.125 billion and $1.130 billion. And full-year product revenue is expected to reach $4.395 billion, representing 27% year-over-year growth.

The company reported a net revenue retention rate of 125% in the current quarter.

Link: https://investors.snowflake.com/news/news-details/2025/Snowflake-Reports-Financial-Results-for-the-Second-Quarter-of-Fiscal-2026/

Veeva Systems Inc. fell 4.3% to $281.03 despite the provider of cloud-based software solutions for the life sciences industry reporting a 17% increase in net income in the fiscal second quarter ending on July 31.

Consolidated revenue inched higher to $789 million from $676.2 million, net income climbed to $200 million from $171 million, and diluted earnings per share soared to $1.19 from $1.04 a year ago.

The company guided third-quarter revenue to be between $790 million and $793 million, non-GAAP operating income between $348 million and $350 million, and non-GAAP diluted earnings per share between $1.94 and $1.95.

Veeva’s full-year guidance is total revenue between $3.13 billion and $3.14 billion, non-GAAP operating income expected to be $1.388 billion, and non-GAAP diluted earnings per share expected to be $7.78.

Veeva is rapidly progressing with industry-specific AI, with initial AI agents launching in December and broader rollouts through 2027. Seven top 20 biopharmas have adopted Vault CRM, which has achieved key milestones and now boasts over 100 customers. Veeva continues to solidify its role in drug development, with all top 20 biopharmas using Veeva eTMF and strong adoption across other solutions. In August, Veeva and IQVIA formed a long-term partnership, resolving all legal disputes.

Link: https://ir.veeva.com/news/news-details/2025/Veeva-Announces-Fiscal-2026-Second-Quarter-Results/default.aspx

Williams Sonoma Inc. plunged 0.08% to $192.01 despite the specialty retailer of products for the home reporting a 14% rise in its earnings in the latest quarter ending on August 3.

Consolidated revenue edged higher to $1.84 billion from $1.79 billion, net income advanced to $247.6 million from $216.9 million, and diluted earnings per share rose to $2.00 from $1.67 a year ago.

During the second quarter, Williams-Sonoma returned $280 million to shareholders, including $199 million in share repurchases and $81 million in dividends, with $903 million remaining under the repurchase program.

Merchandise inventories rose 17.7% to $1.4 billion, reflecting early receipts to offset expected 2025 tariffs.

Comparable brand revenue increased by 3.7%.

Williams Sonoma is raising its fiscal 2025 net revenue guidance, now anticipating growth of 0.5% to 3.5%, including the impact of the 53rd week in fiscal 2024, with comparable sales up 2.0% to 5.0%. Although higher revenues are expected, margin flow-through will be pressured by increased tariffs—including 30% on China, 50% on India and copper, 20% on Vietnam, and 50% on steel and aluminum. The company reiterates its fiscal 2025 operating margin guidance of 17.4% to 17.8% and will revisit it if tariff conditions materially change. Interest income is projected at $30 million, with an effective tax rate of approximately 26.5%.

Link: https://s24.q4cdn.com/161876561/files/doc_financials/2025/q2/WSM-FY-2025-Q2-Earnings-Release.pdf